A Chinese biotech says it spent $23 million to take an Ozempic-style pill to the final clinical trial stage

MindRank's lead drug, MDR-001, is a once-daily pill aimed at the same receptor that Ozempic, Wegovy, and Mounjaro target. It entered the final stage of clinical trials in China in 2025, after a 4.5-year run that the company says cost about $23 million in cumulative R&D. On July 9, 2026, MindRank announced a $52 million Series B to fund the next stage, with Kaiwu Capital as exclusive financial advisor.

GLP-1 is the receptor targeted by the current generation of injectable diabetes and weight-loss drugs. The dominant products on the market today, Ozempic and Wegovy from Novo Nordisk and Mounjaro from Eli Lilly, are weekly injections. An oral, small-molecule GLP-1 pill, taken daily, is the open lane the industry is racing to fill. MindRank, a clinical-stage Chinese company most readers will not have heard of, is now claiming a seat in that race alongside the larger pharmas working on their own oral GLP-1 programs.

The company declined to name a lead investor in the Series B, describing the round only as backed by "a group of institutional and healthcare funds." Stated use of proceeds is to iterate the Molecule Arts Platform (MAP), advance MDR-001's Phase III and prepare commercialization, and push additional pipeline programs forward. MindRank's MAP is the in-house system the company says integrates biology, chemistry, computation, lab evidence, and clinical data through multi-agent AI and generative molecular design.

MDR-001 entered Phase III in China in 2025, roughly 4.5 years after the program was initiated, under trial registry NCT07110766. MindRank frames MDR-001 as an "AI-native" candidate, designed on MAP rather than screened from a traditional high-throughput library.

The $23 million figure is MindRank's own disclosure, and it has specific limits. The company says the number reflects cumulative R&D spend on MDR-001 from program launch to the start of Phase III in China. It does not include the cost of failed candidates that did not advance, the share of platform overhead spread across other programs, or any accounting for what an equivalent program at a large pharma would have spent. Read narrowly, $23 million is the cost of the one program that made it. Read broadly, as a test of the AI-native efficiency thesis, it is closer to a marketing number than an audited benchmark.

The China-only regulatory path is a second caveat. Phase III trials conducted in China are not automatically interchangeable with FDA-conducted Phase III trials in the United States. MindRank's announcement does not lay out a US or global regulatory pathway for MDR-001. The company's broader pipeline, three INDs cleared in China and the United States, suggests an awareness of that gap without committing to it on this program.

The pipeline beyond MDR-001 is real, if early. MindRank says it has five additional preclinical candidates nominated. Founder and CEO Zhangming Niu has built a small organization around MAP. The open question is whether an AI-native pipeline can compress the cost and time from program launch to a registrational-stage study below the conventional small-molecule baseline.

Even before any US regulatory path opens, a successful China Phase III would put MDR-001 into a market where the same injectable incumbents are already expanding. MindRank's stated use of proceeds includes commercialization, which suggests the company sees a domestic path to market even if the broader AI-native efficiency claim has to wait for cross-border validation. The next concrete data point will be the Phase III readout, which has not yet been scheduled publicly. The open question is whether an oral GLP-1 from a small Chinese clinical-stage company can compete with the injectable incumbents, and with the other oral GLP-1 programs already in development.